An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.

Cmax of Emraclidine

Tmax of Emraclidine

AUCt of Emraclidine

AUCtau of Emraclidine

MRCmax of Emraclidine

MRAUCtau of Emraclidine

Cmin of Emraclidine

Cavg of Emraclidine

Terminal phase elimination half-life of Emraclidine

λz of Emraclidine

CL/F of Emraclidine

Vz/F of Emraclidine

PTR of Emraclidine

RacCmax of Emraclidine

RacAUCta of Emraclidine

Cmax of Metabolite (CV-0000364)

Tmax of Metabolite (CV-000036)

AUCtau of Metabolite (CV-000036)

AUCt of Metabolite (CV-000036)

MRCmax of Metabolite (CV-000036)

MRAUCtau of Metabolite (CV-000036)

PANSS is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. The PANSS consists of 3 subscales containing a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms.

The PANSS measures symptom severity of participants with schizophrenia and contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale with a total minimum score of 30 and a maximum score of 210. Baseline was defined as the last value obtained prior to initiation of investigational medicinal product (IMP). Change from baseline for a given endpoint was defined as the value on a given Study Day (Time Point) minus the Baseline Value. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.

Cmax of Emraclidine.

Tmax of Emraclidine.

AUC of Emraclidine.

An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

Number of participants with clinical significant change from baseline in vital sign measurements like systolic and diastolic blood pressure will be assessed.

12-lead resting ECG will be recorded.

Number of participants with clinical significant change in physical examinations will be assessed.

Number of participants with clinical significant change in clinical laboratory test results will be assessed.

The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior, with a higher score denoting more severe suicidal ideation and behavior.

AIMS assesses abnormal involuntary movements, such as tardive dyskinesia, associated with antipsychotic drugs; it measures facial, oral, extremities, and trunk movements, as well as the participant's awareness of abnormal movements. The first 10 items are rated on a none (0) to severe (4) scale. There are an additional 2 items on dental status that are answered yes or no.

BARS is a 4-item rating scale used to assess drug-induced akathisia. The scale comprises items for rating the observable restless movements that characterize the condition, the subjective awareness of restlessness, and any distress associated with the akathisia (each on a 4-point scale from normal \[0\] to severe \[3\]). In addition, there is a global severity for akathisia rated on a 6-point scale (absent \[0\] to severe akathisia \[5\]).

SAS is a 10-item rating scale for assessment of antipsychotic-induced parkinsonism in both clinical practice and research settings. Each item ranges from 0 (normal) to 4 (extreme symptoms). The scale consists of 1 item measuring gait (hypokinesia), 6 items measuring rigidity, and 3 items measuring glabella tap, tremor, and salivation, respectively.

Cmax of Metabolite (CV-0000364)

Tmax of Metabolite (CV-000036)

AUCt of Emraclidine

AUCt of Metabolite (CV-000036)

AUCtau of Emraclidine

Cmin of Emraclidine

Cmin of Metabolite (CV-0000364)

Cavg of Emraclidine

Cavg of Metabolite (CV-0000364)

MRCmax of Emraclidine calculated from Cmax

MRCmax of Metabolite (CV-0000364) calculated from Cmax

MRAUCtau of Emraclidine based on AUCtau

MRAUCtau of Metabolite (CV-000036) based on AUCtau

Terminal phase elimination half-life of Emraclidine

Terminal phase elimination half-life of Metabolite (CV-000036)

β of Emraclidine

β of Metabolite (CV-0000364)

PTR of Emraclidine

PTR of Metabolite (CV-000036)

RacCmax of Emraclidine

RacCmax of Metabolite (CV-0000364)

RacAUCtau of Emraclidine

RacAUCtau of Metabolite (CV-0000364)

CL/F of Emraclidine

Vz/F of Emraclidine

AUCtau of Metabolite (CV-0000364)

The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present (from 1 to 5, with 5 being the most severe). Greater lethality or potential lethality of suicidal behaviors (endorsed on the behavior subscale) indicates increased risk.

The SAS consists of a list of 10 symptoms of parkinsonism. Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms and a score of 4 representing a severe condition. The SAS total score is the sum of the scores for all 10 items.

The AIMS assessment consists of 10 items describing symptoms of dyskinesia. Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms (for item 10, no awareness), and a score of 4 indicating a severe condition (for item 10, awareness, severe distress). In addition, the AIMS includes 2 yes/no questions that address the participant's dental status.

The BARS consists of 4 items related to akathisia. The first 3 items are rated on a 4-point scale, with a score of 0 representing absence of symptoms and a score of 3 representing a severe condition. The global clinical evaluation is made on a 6-point scale, with a score of 0 representing absence of symptom and a score of 5 representing severe akathisia.

Extrapyramidal symptoms will be evaluated using SAS, AIMS, and BARS scales.